Miscellaneous
Lead investigator Philip Mease discusses the findings from the SPIRIT-H2H trial, a phase III head-to-head trial of ixekizumab versus adalimumab in patients with psoriatic arthritis. Find more on Medicine Matters rheumatology This content was originally published on Medicine Matters rheumatology (https://rheumatology.medicinematters.com/) on June 15, 2019.